triheptanoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5399 620-67-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triheptanoin
  • dojolvi
  • UX007
Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement
  • Molecular weight: 428.61
  • Formula: C24H44O6
  • CLOGP: 8.38
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 0
  • TPSA: 78.90
  • ALOGS: -6.01
  • ROTB: 23

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
June 30, 2020 FDA ULTRAGENYX PHARM INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 61.44 57.59 13 55 43938 63445016

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AX17 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Various alimentary tract and metabolism products
FDA CS M0021969 Triglycerides
FDA EPC N0000194023 Medium-chain Triglyceride

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Disorder of fatty acid metabolism indication 39929009
Long-chain fatty acid transport deficiency indication 426387005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100% w/w DOJOLVI ULTRAGENYX PHARM INC N213687 June 30, 2020 RX LIQUID ORAL June 30, 2025 NEW CHEMICAL ENTITY
100% w/w DOJOLVI ULTRAGENYX PHARM INC N213687 June 30, 2020 RX LIQUID ORAL June 30, 2027 INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)

Bioactivity Summary:

None

External reference:

IDSource
D11465 KEGG_DRUG
2P6O7CFW5K UNII
C2604598 UMLSCUI
CHEMBL4297585 ChEMBL_ID
69286 PUBCHEM_CID
DB11677 DRUGBANK_ID
11431 IUPHAR_LIGAND_ID
018432 NDDF
926370002 SNOMEDCT_US
926378009 SNOMEDCT_US
4039553 VANDF
1313234 RXNORM
336029 MMSL
38592 MMSL
d09588 MMSL
C531010 MESH_SUPPLEMENTAL_RECORD_UI
10893 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DOJOLVI HUMAN PRESCRIPTION DRUG LABEL 1 69794-050 LIQUID 0.96 g ORAL NDA 25 sections
DOJOLVI HUMAN PRESCRIPTION DRUG LABEL 1 69794-050 LIQUID 0.96 g ORAL NDA 25 sections
DOJOLVI HUMAN PRESCRIPTION DRUG LABEL 1 69794-050 LIQUID 0.96 g ORAL NDA 25 sections